Compare MTEX & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTEX | TCRX |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 11.8M |
| IPO Year | 1998 | 2021 |
| Metric | MTEX | TCRX |
|---|---|---|
| Price | $9.02 | $0.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 30.7K | ★ 476.9K |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $108,038,000.00 | $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.31 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $3.80 | $0.17 |
| 52 Week High | $9.97 | $1.47 |
| Indicator | MTEX | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 31.96 |
| Support Level | $6.26 | N/A |
| Resistance Level | $9.65 | $0.21 |
| Average True Range (ATR) | 0.58 | 0.02 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 86.21 | 8.01 |
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.